Andrew Kaiser is a seasoned professional in the field of immunotherapy and cellular reprogramming, currently serving as Vice President of Translational Cellular Reprogramming at BioNTech SE since October 2021. With extensive experience at Miltenyi Biotec from 2012 to 2021, Andrew held roles such as Senior Manager and R&D Manager, leading multiple programs focused on T cell therapies and CAR T innovations while overseeing a significant team. Prior positions include post-doctoral roles at the National Cancer Institute and NKI-AVL, where Andrew contributed to advancements in adoptive cell transfer and chimeric TCR design. Andrew holds a PhD in Immunology from Pierre and Marie Curie University and has authored peer-reviewed publications and patents, showcasing a strong track record in clinical trial development and translational research.
This person is not in any teams
This person is not in any offices